PhRMA VP-Drug Regulatory Affairs Beary moving to P&G as medical director in arthritis programs.
PHRMA SENIOR VP-DRUG REGULATORY AFFAIRS BEARY GOING TO P&G Pharmaceuticals to be medical director of arthritis programs. As the top association officer in the science and regulatory affairs area for nine years, John Beary, MD, has been the primary contact with medical groups and has been in charge of FDA relations. Beary's responsibilities at Pharmaceutical Research & Manufacturers of America were scaled back earlier this year from overall medical affairs to drug regulatory issues to permit new association management to begin the search for a new vice president to head scientific and medical affairs ("The Pink Sheet" Feb. 3, T&G-1).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth